GARS1 and peripheral neuropathy: Our long-term goal in these studies, and our rationale for using affected tissues instead of easily obtainable serum or urine samples, is to determine the mechanism by which mutations in Gars cause peripheral neuropathy, which should lead to treatment options based either on supplementation or drug interventions in the affected metabolic pathway.